HTB South

Paediatric care

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir in young children is superior to nevirapine after five years: results from long term follow up of IMPAACT P1060

Long-term safety and efficacy of tenofovir in children

Drug resistance in children after PMTCT and early treatment

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

Rationalising the paediatric antiretroviral formulary in Malawi

Time to first-line failure in the IeDEA cohort

Influence of early ART on antibody detection in children

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

Trials show further benefits for cotrimoxazole in children and adults

FDA approves raltegravir for children older than 4 weeks

Lower immune response to the qHPV vaccine in HIV positive girls

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

WHO 2013 guidelines: what about the missing formulations?

Decreased growth in ART exposed uninfected infants in Botswana

Antiretrovirals, doses and formulations for children

Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial

Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Tenofovir use in children

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

Report of a functional cure in an HIV infected infant

Paediatric TB: glimpses of PK data and a potential new approach to drug development

New UNITAID grants focus on paediatric HIV, TB and malaria

US paediatric guidelines updated

Resistance in infants and children receiving ART in South Africa

ART and adverse birth outcomes in Botswana

Antiviral activity in vitro with S/GSK1265744

Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics

Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings

Update on new antiretrovirals for children and adolescents

Tenofovir prophylaxis for neonates

Efavirenz levels variable in children in the CHAPAS-3 study

Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART

High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

BCG vaccination at birth induces CD4 cell activation in HIV exposed infants

Paediatric formulations of ARVs: including an exciting new class

Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART

High prevalence of d4T-associated lipodystrophy including lipoatrophy in children

Lopinavir/ritonavir monotherapy in children

Stopping treatment after early ART in infants

Delaying ART in childhood can reduce long-term CD4 count in adulthood

Efavirenz under-dosing in children

Treatment response and duration of first line treatment in European infants

Pharmacokinetics of paediatric tenofovir based regimens

Atazanavir pharmacokinetics in infants, children and adolescents

Crushing lopinavir/ritonavir tablets decreases exposure by almost half in children

No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial

Paediatric antiretroviral pipeline: update on etravirine and maraviroc

More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

Prematurity not associated with early mortality in infants on ART

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Lopinavir/ritonavir oral solution toxicity in neonates

Paediatric antiretroviral pipeline: darunavir and raltegravir

Long-term outcomes for infants starting lopinavir/ritonavir at less than 6 months

Effects of antiretroviral exposure through PMTCT strategies on infants in Botswana

Pharmacokinetics of lopinavir/ritonavir in combination with rifampicin based TB treatment in children

New WHO guidelines for children

Post navigation